BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/1/2016 9:28:00 AM | Browse: 2491 | Download: 3209
Publication Name World Journal of Gastroenterology
Manuscript ID 20143
Country Italy
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Manuscript Source Invited Manuscript
All Author List Eleonora Distrutti, Lorenzo Monaldi, Patrizia Ricci and Stefano Fiorucci
Funding Agency and Grant Number
Corresponding Author Eleonora Distrutti, MD, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy. eleonoradistrutti@katamail.com
Key Words Irritable bowel syndrome; Gut microbiota; Probiotics; Prebiotics; Synbiotics; Antibiotics; Fecal transplantation
Core Tip In the last decade, the gut microbiota has provided support to the concept that a disturbed intestinal ecology could promote development and maintenance of symptoms in irritable bowel syndrome (IBS). As a correlate, manipulation of gut microbiota represents a new strategy for the treatment of this multifactorial disease. Probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need for-mation. Fecal transplant has recently gained a new life as therapeutic option for those patients with an altered gut ecosystem, but data on IBS are scanty and randomized, placebo-controlled studies are required.
Publish Date 2016-01-31 11:48
Citation Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol 2016; 22(7): 2219-2241
URL http://www.wjgnet.com/1007-9327/full/v22/i7/2219.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i7.2219
Full Article (PDF) WJG-22-2219.pdf
Full Article (Word) WJG-22-2219.doc